GlassScriptPhysician profile
Tyler Alan Peterson
NPI 1467800243
$1,957.82
in general payments reported to CMS, 2019-2025
29 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2022: $202 · 2023: $424 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $196.97 | 2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $179.04 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $177.43 | 2019-2025 | |
| Amgen INC. | $173.38 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $168.07 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $154.43 | 2025 | |
| Glaxosmithkline, LLC. | $100.31 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Edwards Lifesciences Corporation | $96.16 | 2025 | Pascal |
| Lundbeck LLC | $89.47 | 2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.39 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $71.37 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $56.10 | 2019-2023 | |
| Dexcom, INC. | $43.18 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $36.97 | 2023-2025 | Gardasil 9, M-M-R II, Rotateq |
| Becton, Dickinson and Company | $35.57 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.19 | 2022 | |
| Sumitomo Pharma America, INC. | $25.35 | 2025 | Gemtesa |
| Genzyme Corporation | $22.72 | 2023 | |
| Irhythm Technologies, INC. | $21.83 | 2022 | |
| Mannkind Corporation | $21.66 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.19 | 2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $21.06 | 2023 | Evkeeza |
| Idorsia Pharmaceuticals US INC | $19.45 | 2023 | Quviviq |
| Lilly USA, LLC | $18.13 | 2025 | Kisunla |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $17.01 | 2019 | |
| Bausch Health US, LLC | $15.25 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.